Tekmira Provides Periodic Update to Litigation
December 21, 2011 17:30 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Tekmira Secures $3 Million Financing
December 21, 2011 16:50 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced it...
Tekmira Pharmaceuticals Receives Approval from FDA to Initiate TKM-Ebola Phase 1 Clinical Trial
November 28, 2011 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 28, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Tekmira's LNP Technology Enables Alnylam's ALN-TTR01 Clinical Data
November 21, 2011 08:34 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR)(TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Files for an Injunction in the Supreme Court of British Columbia Seeking Return of Confidential Documents
November 16, 2011 08:30 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 16, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed today...
Tekmira Provides Corporate Update and Announces Third Quarter 2011 Results
November 08, 2011 16:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 8, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its...
Tekmira Conference Call and Webcast Advisory: Third Quarter 2011 Operating Results and Corporate Update
November 03, 2011 16:30 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Provides Periodic Update to Litigation
October 20, 2011 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 20, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Tekmira and Collaborators Demonstrate Efficacy of RNAi Against Hepatitis C Virus
September 12, 2011 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 12, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Tekmira to Present at the Stifel Nicolaus Annual Healthcare Conference
September 01, 2011 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...